Pancreatic beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes

Regul Pept. 2010 Feb 25;160(1-3):175-80. doi: 10.1016/j.regpep.2009.12.004. Epub 2010 Jan 13.

Abstract

This study investigated the effects of strict glycaemic control on beta-cell function in nine obese subjects with type 2 diabetes (T2DM), using graded glucose infusions together with infusions of saline or GLP-1 before (HbA(1)c: 8.0+/-0.4%) and after four weeks of near-normalization of blood glucose (BG) using insulin (mean diurnal BG: 6.4+/-0.3 mmol/l; HbA(1)c: 6.6+/-0.3%). Nine matched healthy subjects acted as controls. In controls, area-under-curve (AUC) for amylin, C-peptide and proinsulin were higher with GLP-1 than saline (P<0.001). The AUC amylin/C-peptide ratio was similar on both days, while AUC proinsulin/C-peptide ratio was higher with GLP-1 (P=0.02). In the patients, amylin, C-peptide and proinsulin AUCs were unaltered by near-normoglycaemia per se. Proinsulin responses to GLP-1 were unchanged, but amylin and C-peptide AUCs increased (P<0.05) after insulin treatment, and AUC amylin/C-peptide ratios rose to control levels. Near-normoglycaemia tended to reduce AUC proinsulin/C-peptide ratio, which was significant (P=0.04) with GLP-1, but still higher than with saline (P=0.004). In conclusion, amylin, C-peptide and proinsulin responses to glucose were unaffected by four weeks of near-normoglycaemia, whereas GLP-1 increased amylin and C-peptide secretion and amylin/C-peptide ratio. Near-normoglycaemia reduced proinsulin/C-peptide ratio during stimulation with GLP-1, suggesting that strict glycaemic control might ameliorate some of the disturbances in beta-cell function characterizing T2DM.

Publication types

  • Clinical Trial

MeSH terms

  • Amyloid / metabolism
  • Area Under Curve
  • Blood Glucose / analysis
  • Blood Glucose / drug effects*
  • C-Peptide / metabolism
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Female
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / pharmacology*
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Glucose / administration & dosage
  • Humans
  • Incretins / pharmacology*
  • Insulin / administration & dosage
  • Insulin / pharmacology
  • Insulin-Secreting Cells / drug effects*
  • Islet Amyloid Polypeptide
  • Male
  • Middle Aged
  • Proinsulin / metabolism
  • Time Factors

Substances

  • Amyloid
  • Blood Glucose
  • C-Peptide
  • Incretins
  • Insulin
  • Islet Amyloid Polypeptide
  • Glucagon-Like Peptide 1
  • Proinsulin
  • Glucose